An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects

Trial Profile

An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2017

At a glance

  • Drugs Perampanel (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 28 Apr 2017 Results assessing long term efficacy and safety presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 06 Dec 2016 Status changed from active, no longer recruiting to completed, as per an abstract presented at the 70th Annual Meeting of the American Epilepsy Society.
    • 06 Dec 2016 Results presented at the 70th Annual Meeting of the American Epilepsy Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top